Back to Search
RUBEN MESA, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1962480475IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
2023-00022(NC)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
2023-00022(NC)
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
2023-00022(NC)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
MAYO MEDICAL SCHOOL
Class of 1995
Research & Publications (20)
Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
PMID 19552608·Expert Opin Emerg Drugs·2009
6-review
How I treat symptomatic splenomegaly in patients with myelofibrosis.
PMID 19332765·Blood·2009
6-review
Pegylated interferon for the treatment of high-risk essential thrombocythemia.
PMID 16219553·Haematologica·2005
8-other
Overexpression of Rab22a hampers the transport between endosomes and the Golgi apparatus.
PMID 15748882·Exp Cell Res·2005
7-preclinical
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia.
PMID 12010817·Blood·2002
4-observational
Rab22a affects the morphology and function of the endocytic pathway.
PMID 11739636·J Cell Sci·2001
7-preclinical
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia.
PMID 11071630·Blood·2000
4-observational
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
PMID 19262601·Leukemia·2009
8-other
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
PMID 19396855·Am J Hematol·2009
8-other
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
PMID 19250674·Leuk Res·2009
4-observational
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
PMID 19215287·Eur J Haematol·2009
8-other
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
PMID 19179475·Blood·2009
8-other
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
PMID 18988864·Blood·2009
4-observational
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
PMID 19641523·Leukemia·2009
6-review
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
PMID 19652059·J Clin Oncol·2009
3-trial
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.
PMID 18723481·Mol Cancer Ther·2008
8-other
Myeloproliferative disorder-associated massive splenomegaly.
PMID 18496494·Clin Adv Hematol Oncol·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 5 locations total
- Address
- 945 N 5TH ST
ALBEMARLE, NC 28001 - Phone
- (980) 323-7790
Locations (5)
Practice Location
945 N 5TH ST, ALBEMARLE, NC
(980) 323-7790
Practice Location
1021 MOREHEAD MEDICAL DR, CHARLOTTE, NC
(980) 442-2000
Practice Location
4525 CAMERON VALLEY PKWY, CHARLOTTE, NC
(704) 302-8300
Practice Location
100 MEDICAL PARK DR, CONCORD, NC
(704) 403-1370
Practice Location
1550 FAULK ST, MONROE, NC
(980) 442-0430
Quick Facts
- NPI
- 1962480475
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 5
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile